Working… Menu
Trial record 11 of 91 for:    hidradenitis suppurativa

Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study) (SHARPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02808975
Recruitment Status : Completed
First Posted : June 22, 2016
Last Update Posted : November 6, 2019
Information provided by (Responsible Party):

Brief Summary:
The objective of this study is to assess the safety and efficacy of adalimumab prior to surgery in subjects with moderate to severe Hidradenitis Suppurativa (HS) who are surgical candidates.

Condition or disease Intervention/treatment Phase
Hidradenitis Suppurativa (HS) Drug: Adalimumab Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 206 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 4, Double-blind, Randomised, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa
Actual Study Start Date : July 18, 2016
Actual Primary Completion Date : May 16, 2019
Actual Study Completion Date : October 16, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Adalimumab

Arm Intervention/treatment
Placebo Comparator: Placebo
Participants randomized to the placebo arm will receive placebo.
Drug: Placebo
Weekly subcutaneous injection

Active Comparator: Adalimumab
Participants randomized to the adalimumab arm will receive active drug, adalimumab.
Drug: Adalimumab
Weekly subcutaneous injection
Other Name: Humira

Primary Outcome Measures :
  1. Proportion of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) [ Time Frame: At Week 12 ]
    HiSCR defined as at least a 50% reduction in the AN count with no increase in abscess count and no increase in draining fistula count relative to Baseline.

Secondary Outcome Measures :
  1. Proportion of participants achieving HiSCR-es [ Time Frame: At Weeks 12 and 24 ]
    The proportion of participants achieving HiSCR-es (defined as the Hidradenitis Suppurativa Clinical Response excluding the HS surgical site)

  2. Proportion of participants that require less extensive surgery than the surgical plan (determined at Baseline) or no surgery [ Time Frame: At Week 12 ]
    The proportion of participants that require less extensive surgery than the surgical plan or no longer require surgery.

  3. Percent change in surface area of the Hidradenitis Suppurativa (HS) surgical site [ Time Frame: From Week 0 to Week 12 ]
    Assessing change in surface area of the HS surgical site from baseline to week 12, before surgery.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participant must have skin lesions that are diagnostic of Hidradenitis Suppurativa (HS) for at least 1 year (365 days) prior to the Baseline visit
  • Participant must have at least 3 distinct anatomical regions involved with inflammatory ( also termed 'active') HS lesions; plus

    • either one axilla or one inguinal region (limited to the inguino-crural fold and adjacent areas) that requires excisional surgery, and
    • with at least one of the other affected HS regions (e.g., contralateral inguinal region, buttocks, inframammary region) rated as Hurley Stage II or III
  • Participant must have a total abscess and inflammatory nodule (AN) count of greater than or equal to 3 at the Baseline visit within the HS non-surgical sites
  • The HS surgical site must contain at least one active HS lesion
  • The HS surgical site must require excisional surgery and is large enough to require healing by secondary intention as assessed by the designated surgeon

Exclusion Criteria:

  • Has a draining fistula count of greater than 20 at the Baseline visit
  • Requires surgery at any anatomical site other than an unilateral axilla or inguinal region site
  • Requires surgical management prior to Week 13
  • Requires, based on the designated surgeon's assessment, excisional surgery with primary closure as the method of closure being most beneficial for the participant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02808975

  Show 54 Study Locations
Sponsors and Collaborators
Layout table for investigator information
Study Director: AbbVie Inc. AbbVie

Additional Information:
Layout table for additonal information
Responsible Party: AbbVie Identifier: NCT02808975     History of Changes
Other Study ID Numbers: M15-574
2015-005161-23 ( EudraCT Number )
First Posted: June 22, 2016    Key Record Dates
Last Update Posted: November 6, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by AbbVie:
Hidradenitis Suppurativa
inguinal region
Hurley Stage I, II, or III
secondary intention
abcess and inflammatory nodule (AN) count
Additional relevant MeSH terms:
Layout table for MeSH terms
Hidradenitis Suppurativa
Sweat Gland Diseases
Skin Diseases
Skin Diseases, Bacterial
Bacterial Infections
Skin Diseases, Infectious
Anti-Inflammatory Agents
Antirheumatic Agents